clinical trial · NCT06106828
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Thyroid Eye DiseaseSatralizumabPlacebo
brief summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
started
Nov 15, 2023
primary completion
Jul 24, 2025
completion
Jun 25, 2026
last updated
Aug 12, 2026
official title
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol